PORT-77 / BridgeBio - LARVOL DELTA

EPP: GATEWAY: A Phase 2a Study of PORT-77 in Adults With Erythropoietic Protoporphyria (clinicaltrials.gov) - P2 | N=14 | Enrolling by invitation | Sponsor: Portal Therapeutics, Inc.

New P2 trial • Genetic Disorders • Metabolic Disorders

Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study of PORT-77 Administered to Healthy Adult Participants (clinicaltrials.gov) - P1 | N=108 | Recruiting | Sponsor: Portal Therapeutics, Inc. | Not yet recruiting ➔ Recruiting | Trial completion date: Dec 2024 ➔ Aug 2025 | Trial primary completion date: Dec 2024 ➔ Aug 2025

Enrollment open • Trial completion date • Trial primary completion date

PORT-77, a Novel and Potent Inhibitor of ABCG2, Protects Against Skin Photo Toxicity and Liver Damage in a Mouse Model of Erythropoietic Protoporphyria (EPP) (ASH 2024) - "Conclusions In summary, in vitro pharmacology data and in vivo efficacy data in a mouse model of EPP provide a strong biological rationale for developing PORT-77 for the treatment of the patients with EPP. The safety and PK of PORT-77 are currently being evaluated in a phase 1 study."

Preclinical • Dermatology • Fibrosis • Genetic Disorders • Hematological Disorders • Hepatology • Immunology • Liver Cirrhosis • Metabolic Disorders • Pain • ABCG2 • FECH